

1 **Supplemental oxygen costs and equipment utilization in a low-income population with ILD or**
2 **COPD**

3

4 Kristopher P. Clark, MD^{1,2}; Daniel J. Kass, MD¹; Howard B. Degenholtz, PhD³

5

6 ¹The Dorothy P. and Richard P. Simmons Center for Interstitial Lung Disease, University of
7 Pittsburgh, Department of Medicine, Division of Pulmonary, Allergy, Critical Care, and Sleep
8 Medicine, Pittsburgh, PA

9 ²State University of New York at Buffalo, Jacobs School of Medicine and Biomedical Sciences,
10 Division of Pulmonary, Critical Care, and Sleep Medicine, Buffalo, NY

11 ³University of Pittsburgh, School of Public Health, Department of Health Policy and
12 Management, Pittsburgh, PA

13

14 **ORCID IDs:** 0009-0007-1034-9483 (K.P.C.); 0000-0001-6597-7830 (D.J.K.); 0000-0003-1986-
15 7360 (H.B.D.)

16

17 **CORRESPONDING AUTHOR**

18 Kristopher Clark, MD

19 SUNY at Buffalo Jacobs School of Medicine and Biomedical Sciences

20 Buffalo General Medical Center

21 100 High Street, Room B814

22 Buffalo, NY 14203

23 kclark4@buffalo.edu

24

25 **AUTHORS' CONTRIBUTIONS:** KPC, DJK, and HBD conceived and designed the study. KPC and
26 HBD obtained and analyzed the data. KPC, DJK, and HBD interpreted the data and drafted the
27 manuscript.

28

29 **SOURCES OF SUPPORT:** None

30

31 **WORD COUNT:** 3,483

32

33 **ABSTRACT**

34 **Rationale:** Supplemental oxygen is often prescribed to patients with interstitial lung disease
35 (ILD) and chronic obstructive pulmonary disease (COPD). The specific costs of oxygen therapy in
36 these diseases have not been fully described in patients living in the United States.

37 **Objectives:** Estimate Medicaid/Medicare costs for supplemental oxygen, characterize
38 differences in oxygen equipment utilization, and identify factors impacting the costs of
39 supplemental oxygen therapy in ILD and COPD.

40 **Methods:** We reviewed claims data for years 2016-2020 for Pennsylvania residents with ILD or
41 COPD who were dually eligible for Medicaid/Medicare and enrolled in traditional fee-for-service
42 Medicare. A generalized estimated equation (GEE) model was used to identify variables
43 associated with annual oxygen costs.

44 **Measurements and Main Results:** A greater proportion of paid claims in ILD were for oxygen
45 services (40.3% vs 22.0%) and for high flow oxygen (4.2% vs 2.2%), though ILD represented the
46 minority of paid oxygen claims (5.2%). Oxygen cost approximately \$65/month for both groups.
47 Most oxygen claims ($\geq 94\%$) were for stationary concentrators. Liquid devices and stationary gas
48 were the least utilized equipment. Lower costs were associated with living in a competitive
49 bidding area and with markers of advanced age and worse health status.

50 **Conclusions:** Oxygen utilization is greater in ILD but is only a small portion of total oxygen claims
51 compared to COPD. Costs and equipment utilization were similar between groups. Liquid
52 oxygen claims were rare even among subjects requiring high flow. Oxygen therapy is common in
53 these diseases and likely represents a significant contribution to total healthcare costs.

54

55 **ABSTRACT NUMBER OF WORDS:** 249

56

57 **KEY WORDS:** Lung Diseases, Interstitial; Pulmonary Disease, Chronic Obstructive; Oxygen

58 Inhalation Therapy; Competitive Bidding; Health Care Costs

59 INTRODUCTION

60 In the United States, supplemental oxygen therapy is recommended for patients with chronic
61 obstructive pulmonary disease (COPD) and interstitial lung disease (ILD) who have hypoxemia at
62 rest or with exertion(1). These recommendations are based primarily on studies of long-term
63 oxygen therapy (LTOT) which show improved mortality in patients with COPD(2,3). Oxygen
64 therapy is common in both diseases(4-7) and is associated with increased healthcare costs and
65 resource utilization(6,8-12). Healthcare spending on chronic respiratory diseases is estimated at
66 over \$100 billion per year(13,14); however, limited data exists on the costs associated with
67 oxygen therapy in ILD and COPD, and little is known about how these patients utilize oxygen
68 equipment or what factors contribute to oxygen costs in these diseases.

69

70 Supplemental oxygen is delivered from stationary or portable compressed gas tanks, liquid
71 oxygen reservoirs/canisters, or oxygen concentrators. These devices differ in weight, ease of
72 use, capacity to provide high oxygen flow delivery, and cost(15). Patients with ILD and COPD are
73 often eligible for Medicare which provides coverage for durable medical equipment (DME)
74 services including supplemental oxygen equipment and supplies. The Centers for Medicare and
75 Medicaid Services (CMS) provides coverage for rented oxygen equipment/supplies including a
76 50% payment increase for equipment delivering >4 L/min(16,17). While the prescription of
77 oxygen therapy is determined by a medical provider, the type of equipment a patient receives is
78 often at the discretion of the locally contracted DME supplier. In 2011, CMS instituted a
79 competitive bidding program (CBP) designed to lower costs for oxygen and other DME(18,19).
80 While competitive bidding reduced DME spending(20-22), outside observers and patient

81 advocacy groups contend that these changes also resulted in a decrease in DME suppliers and
82 impaired patients' access to supplemental oxygen services(23-25). This has prompted the
83 drafting of the Supplemental Oxygen Access Reform (SOAR) Act which aims to improve oxygen
84 access and payment structure(26).

85

86 We chose to study oxygen costs and utilization in patients who were dually eligible and
87 receiving both Medicaid and Medicare fee-for-service (FFS) benefits as this represents
88 vulnerable, low-income patients likely to have high disease burden. This also allowed us to focus
89 on CMS policy regarding supplemental oxygen payments. We conducted this study of oxygen
90 claims in dually eligible Pennsylvania residents with a diagnosis of ILD or COPD. Our objectives
91 were to 1) estimate the costs for supplemental oxygen therapy, 2) characterize differences in
92 utilization of oxygen delivery equipment, and 3) identify factors associated with increased costs
93 of supplemental oxygen therapy in these diseases.

94

95 **METHODS**

96 *Data Source*

97 We reviewed Pennsylvania Medicare and Medicaid claims paid between January 1, 2016, and
98 December 31, 2020. The data include beneficiary demographics and line-item DME claim
99 payment amounts. Competitive bidding areas (CBA) were determined by matching beneficiary
100 data to 2021 CBA zip codes(27) which were stable when compared to zip code data from earlier
101 years (**Supplement 1**).

102

103 *Study Population*

104 Subjects were dually eligible to receive both Medicaid and Medicare benefits for ≥ 1 month in a
105 calendar year. Subjects enrolled in Medicare Advantage or Special Needs Plans were excluded
106 since encounter data were not available. Subjects were required to have ≥ 2 outpatient or ≥ 1
107 inpatient claims associated with a diagnosis of ILD or COPD based on International Disease
108 Classification (ICD-10) coding (**Supplement 2**). ILD was defined by ICD J84 series which
109 represents fibrotic and interstitial diseases including idiopathic pulmonary fibrosis (IPF), the
110 most common form of ILD. COPD was defined using a validated coding algorithm developed by
111 the Chronic Condition Data Warehouse (CCW)(28). Subjects were excluded if they received
112 nursing home care or were non-Pennsylvania residents (**Supplement 3**).

113

114 *Supplemental Oxygen Use*

115 Subjects were identified as oxygen users if they had ≥ 1 paid claim in a calendar year associated
116 with a Healthcare Common Procedure Coding System (HCPCS) code for oxygen equipment
117 (**Supplement 4**). Claims were analyzed based on equipment type (compressed gas, liquid, or
118 concentrator), whether equipment was stationary or portable, and low versus high flow
119 delivery. We defined high flow as equipment coded for providing >4 L/min to align with CMS
120 reimbursement policy(16).

121

122 *Comorbidities*

123 Comorbid conditions expected to be associated with supplemental oxygen use (tobacco use,
124 heart failure, pulmonary hypertension) were included in the model. To control for underlying

125 health status, we constructed a count of 27 other comorbid conditions based on the validated
126 set of algorithms (1999-2021) available from the CCW(28). See **Supplement 5** for definitions and
127 prevalence rates of comorbidities.

128

129 *Statistical Analyses*

130 The primary outcome was total Medicare/Medicaid payments for oxygen equipment. Chi-
131 squared test at $\alpha=0.05$ was used to compare median payment amounts. The total monthly
132 payment was calculated for each beneficiary using the total annual spending by both Medicaid
133 and Medicare divided by the number of months of eligibility that year. Annualized payments
134 were estimated by top/bottom-coding total monthly payment at the 95th-percentile to
135 eliminate outliers and multiplying by 12. Subcategories with fewer than 10 observations are
136 redacted.

137

138 A generalized estimating equation (GEE) was estimated using the number of months of
139 eligibility per year as an offset term. This approach was chosen to account for repeated
140 observations of beneficiaries across multiple years. The model was adjusted for demographic
141 and other covariates described above. Beneficiaries with both ILD and COPD diagnoses were
142 included in the ILD cohort for all analyses. A sensitivity analysis was performed with these
143 subjects included in the COPD cohort. All analyses were performed using StataSE version 18.

144

145 This study was determined to be exempt from human subjects research by the Institutional
146 Review Board at the University of Pittsburgh.

147

148 **RESULTS**

149 A total of 2,297 unique beneficiaries with ILD and 72,412 with COPD were included in this study.

150 Baseline characteristics are reported using the first year each beneficiary appeared in the data

151 (**Table 1**). Mean (SD) age was 67.6 (14.0) for ILD and 64.5 (12.4) for COPD. A majority of subjects

152 in both cohorts were female and non-Hispanic white. A majority of subjects in both cohorts

153 were residents of non-rural areas and/or resided in a CBA. A total of 32.0% of ILD and 25.2% of

154 COPD beneficiaries were receiving home and community-based services. More than half of the

155 beneficiaries in both cohorts had ≥ 4 comorbidities. In the first year of study inclusion, a greater

156 proportion of beneficiaries with ILD compared to COPD had claims paid for any oxygen

157 equipment (34.5% vs 18.4%) and high flow oxygen (1.7% vs 0.5%).

158

159 The 2,297 ILD subjects had a total of 4,344 person-years during the study period (i.e., unique

160 beneficiary who met the inclusion criteria could appear in more than one calendar year); 40.3%

161 of person-years (1,752) had at least one claim for oxygen services. The 72,412 COPD subjects

162 had a total of 144,816 person-years during the study period; 22.0% of person-years (31,864)

163 had at least one claim for oxygen services. ILD subjects had a greater proportion of oxygen

164 claims across all five study years (**Supplement 6**). Of all person-year claims for oxygen services, a

165 greater proportion of ILD claims were coded high flow oxygen (4.2%) compared to COPD (2.2%).

166 Despite having a greater proportion of oxygen claims, ILD represented only 5.2% of all oxygen

167 claims and 9.0% of all high flow claims.

168

169 The total amount of oxygen payments made during the five-year study period was \$22,216,939
170 of which 76.5% (\$16,994,808) were made by Medicare. Of the total combined
171 Medicare/Medicaid payment amount during the study period, 5% (\$1,107,372) was for ILD and
172 95% (\$21,109,567) was for COPD. The median (IQR) monthly payment for all oxygen claims was
173 \$64.63 (\$35.04-\$94.56) for ILD and \$65.84 (\$33.63-\$96.70) for COPD (p-value=0.985). Median
174 monthly claim payments by calendar year ranged from \$59.57-\$74.11 for ILD and \$56.57-\$78.39
175 for COPD (**Figure 1**).

176
177 At least 94% of paid oxygen claims in both cohorts included stationary oxygen concentrators. A
178 total of 69.2% of ILD and 62.8% of COPD claims included payments for portable gas cannisters
179 while 16.3% of ILD and 11.7% of COPD claims included payments for portable concentrators.
180 Less than 2.5% of claims in both cohorts included liquid oxygen (portable or stationary). A
181 similar utilization pattern was seen for claims coded for high flow delivery (**Figure 2**).

182
183 Median monthly payments varied by equipment type and ranged from \$12.92-\$54.67 for ILD
184 and \$13.78-\$56.83 for COPD. For all paid claims and for high flow claims, the highest payment
185 was for stationary concentrators and the lowest payment was for portable gas. With the
186 exception of portable gas (p=0.020), there was no significant difference in median monthly
187 equipment payments between cohorts. In comparing payments for low vs high flow equipment,
188 high flow stationary concentrator payments were greater for COPD only (p-value <0.001). All
189 other equipment payments for high flow claims were not significantly different from low flow
190 claims (**Table 2**)

191

192 A GEE model for repeated measures was performed to identify variables associated with higher
193 annual oxygen payments among those with paid oxygen claims. As nearly all claims ($\geq 94\%$) in
194 both cohorts included stationary oxygen concentrators, we restricted the analysis to only these
195 subjects and defined the dependent variable as the additional cost above and beyond that for a
196 stationary concentrator. The model was adjusted for age, sex, race, residence in a non-metro
197 area or CBA, long-term services and support use, diagnoses that may impact oxygen use
198 (tobacco use, heart failure, pulmonary hypertension), count of other comorbidities, whether
199 the oxygen claim was coded for high flow, and primary diagnosis (ILD vs COPD). Due to small
200 sample sizes, we combined stationary and portable services for gas and liquid oxygen (e.g., gas
201 stationary or portable, liquid stationary or portable).

202

203 **Table 3a** shows the results of the GEE model. Of beneficiaries who had payments for stationary
204 concentrators, variables significantly associated with higher annual oxygen claim payments (p-
205 value < 0.05) included race other than Hispanic or non-Hispanic white or black, living in a non-
206 metro location, having a diagnosis of heart failure, receiving gas or liquid oxygen or receiving
207 portable concentrators in addition to a stationary concentrator. Increasing age, receiving home-
208 based care, residing in a CBA, current or prior tobacco use, and increasing number of
209 comorbidities were associated with lower annual oxygen claim payments. Increasing age and
210 number of comorbidities were inversely related to payments for additional ambulatory oxygen
211 equipment. Sex, a diagnosis of pulmonary hypertension, whether the oxygen claim was coded
212 for high flow, and a diagnosis of ILD were not significantly associated with annual oxygen claim

213 payments. The cost of oxygen varied based on the combination of equipment that subjects
214 receive. Subjects who only received stationary concentrators had estimated annual costs of
215 \$964 for ILD and \$945 for COPD. Subjects who had both stationary concentrators and liquid
216 oxygen had an estimated annual cost \$1,164 for ILD and \$1,144 for COPD. The estimated annual
217 cost for subjects with a stationary oxygen concentrator and gas oxygen was \$1,027 for ILD and
218 \$1,008 for COPD. The estimated annual cost for subjects with both stationary and portable
219 oxygen concentrators was \$1,241 for ILD and \$1,222 for COPD (**Table 3b**).

220

221 In a sensitivity analysis where beneficiaries with dual ILD and COPD diagnoses were included in
222 the COPD cohort, baseline characteristics and findings from the final GEE model were similar
223 with the exception being that there was no longer a significant difference in the number of
224 oxygen claims at baseline between cohorts (p-value=0.754) (**Supplement 7**).

225

226 **DISCUSSION**

227 The results of our study demonstrate that among Pennsylvania residents dually eligible to
228 receive Medicare and Medicaid, a greater proportion of beneficiaries with ILD compared to
229 COPD used supplemental oxygen and were more likely to have a high flow rate (>4 L/min);
230 however, COPD beneficiaries represented the vast majority (95%) of all paid oxygen claims. The
231 utilization of equipment other than oxygen concentrators was low in both groups even among
232 those receiving high flow rates. Having additional oxygen equipment was associated with
233 increased cost but was less common among older people and those with multiple chronic
234 conditions.

235
236 ILD and COPD are associated with high health care costs and health resource utilization(6,8-12).
237 In a study examining health care spending between 1996 and 2016, both ILD and COPD were
238 identified as being among the top 100 most expensive health conditions with spending in 2016
239 estimated at \$2.1 billion and \$34.3 billion respectively(13). While these estimates did not
240 include DME costs, other studies have found that DME use and specifically the use of
241 supplemental oxygen are also associated with increased healthcare costs and
242 utilization(6,11,12). Physician/DME services contribute an additional \$100 billion in
243 Medicare/Medicaid expenses each year(29). Our findings add to the existing literature by
244 providing estimates on the cost of oxygen services in ILD and COPD in low-income patients living
245 in the U.S.

246
247 We also found that payments for specific oxygen delivery systems did not vary significantly
248 between ILD and COPD beneficiaries. We found that the vast majority of paid oxygen claims
249 ($\geq 94\%$) included stationary concentrators and that stationary concentrators were associated
250 with the highest median monthly payment at approximately \$55-\$57. Our findings align with
251 those of a prior study of CMS DME claims from 2013-2019 which identified stationary oxygen
252 concentrators as the highest volume respiratory DME product, utilized by 2.32% of all Medicare
253 beneficiaries in 2019(30). Both this study and our study identified low utilization rates for other
254 delivery devices including liquid oxygen. Society guidelines recommend portable liquid oxygen
255 for patients requiring >3 L/min and who are active outside the home(1); however, we found that
256 only 2.9% of all high flow portable oxygen claims were for portable liquid oxygen. It is possible

257 that liquid oxygen utilization rates are low due to decreased availability of this device,
258 potentially as a result of CMS's competitive bidding program (CBP). Our estimated monthly
259 median costs differ from those found in a recent review of supplemental oxygen spending in
260 Medicare beneficiaries with COPD which estimated monthly mean costs ranging between \$687
261 to \$771(22). This may be due to different methodologies in cost estimation and which payments
262 were included. Our study focused only on payments made by Medicaid/Medicare and did not
263 include other insurance payments or beneficiary out-of-pocket expenses.

264
265 As previously noted, CMS implemented the CBP in 2011 as a measure to decrease CMS
266 expenditures and beneficiary out-of-pocket expenses on selected DME with high utilization
267 rates and high costs(18). Oxygen equipment is one of the most frequently prescribed DME and
268 is included in the CBP(31). Our model found that living in a CBA was associated with lower
269 oxygen costs, consistent with reports by CMS and other government agencies that the CBP
270 lowered costs of DME(31-33). These agencies also report that the CBP has not negatively
271 impacted clinical outcomes or disrupted DME supply, assertions that were also noted in a recent
272 review of early CBP oxygen claims data in patients with COPD(22). However, numerous outside
273 observers including researchers and advocacy groups have raised concerns that the CBP has
274 resulted in a decreased number of DME suppliers and disrupted access to DME services
275 including liquid oxygen(23-25,34). It has been reported that the number of DME suppliers
276 contracted by CMS to provide oxygen equipment has decreased over time and that the
277 percentage of beneficiaries using oxygen DME has also decreased with the greatest change seen
278 with stationary (-89%) and portable (-86%) liquid oxygen devices(30). The reduction in liquid

279 oxygen utilization has raised concerns that the CBP resulted in more limited access to this
280 therapy(23-25,35). Liquid oxygen is considered to be a more ideal delivery method for patients
281 who require high flow rates due to its lighter weight and longer duration of use with higher
282 flows compared to compressed gas tanks; however, it is likely more costly for DME suppliers to
283 maintain and deliver this form of oxygen therapy which may limit its availability. While many
284 stationary concentrators can meet high flow demands, portable oxygen concentrators currently
285 can not. This limits the portable oxygen options for patients requiring higher flow. The reduced
286 availability and utilization of portable liquid oxygen may have negative impacts on patients'
287 mobility and quality of life. These concerns have led to the drafting of the Supplemental Oxygen
288 Access Reform (SOAR) Act which aims to improve oxygen access and change how oxygen
289 equipment is reimbursed(26). While we did not compare oxygen costs or utilization over time
290 or to pre-competitive bidding data, our findings, which included both COPD and ILD diagnoses,
291 suggest that there are limitations in oxygen equipment utilization, at least among low-income
292 patients including those who require high flow oxygen. It is possible these limitations resulted
293 from changes implemented by the CBP.

294

295 In addition to living in a CBA, we also found that advanced age and increased number of
296 comorbidities were associated with reduced oxygen payments. Further analysis revealed that
297 these findings were primarily related to reduced payment for portable oxygen devices. Whether
298 this means that older and sicker patients are less mobile or less likely to undergo ambulatory
299 oxygen assessments is not known. Lastly, current or prior tobacco use was associated with a

300 lower cost, possibly due to prescribers withholding oxygen prescriptions to patients who
301 actively smoke due to increased risk of fire and injury.

302

303 Increased oxygen costs were associated with living in a non-metro area. Greater than 98% of
304 non-metro claims are excluded from a CBA. We also found that non-Hispanic black and non-
305 Hispanic, non-white or non-black race were associated with higher costs compared to non-
306 Hispanic whites. Both of these race/ethnic groups had a greater proportion of beneficiaries
307 residing within CBAs compared non-Hispanic whites. Racial and ethnic minorities have been
308 shown to bear a disproportionate economic burden related to healthcare costs secondary to
309 inequities in disease burden, morbidity, and premature death(36). Such inequities may also be
310 found in oxygen equipment utilization as well which may account for this finding. Future studies
311 should further explore the impact race/ethnicity, income, and education have on oxygen
312 utilization.

313

314 A diagnosis of heart failure was also associated with increased costs while pulmonary
315 hypertension was not. Pulmonary hypertension is often associated with oxygen needs and may
316 be more common in patients with ILD(37,38). It is possible that our study was underpowered to
317 detect the true effect of this comorbidity. Lastly, while CMS provides 50% increased payment to
318 claims coded for providing high flow (>4 L/min)(17), with the exception of stationary
319 concentrators for COPD, we did not find that payments for high flow claims were significantly
320 greater than claims for ≤ 4 L/min. It may be that our study was underpowered to detect such
321 differences given the low number of high flow claims in our dataset.

322

323 Our study has several strengths. To our knowledge, we are the first study to quantify the cost of
324 oxygen spending in ILD in the U.S. and compare these costs to COPD. We were able to maximize
325 our sample size by using claims data across five years which allowed us to not only quantify the
326 use and cost of oxygen but to assess the impact other parameters have on oxygen costs. By
327 focusing the study on dually eligible beneficiaries, we were able to estimate actual Medicare
328 and Medicaid expenses for oxygen supplies for a vulnerable and policy-relevant population.

329

330 Our study also has several limitations. Our results may not be generalizable to beneficiaries
331 receiving other Medicare or Medicaid services, those with substantial out-of-pocket expenses,
332 or those who have oxygen services paid through private insurance carriers. Results may not be
333 generalizable to patients living in other states; however, Pennsylvania is a large state with both
334 large metropolitan areas and large rural areas and is demographically similar to the US average.
335 Nevertheless, recent data from our center suggest that regional differences in air quality may
336 adversely impact the prognosis of pulmonary fibrosis(39), thus oxygen utilization may have
337 regional variation due to these exacerbating factors. Due to increased enrollment in Medicare
338 Advantage plans over the course of our study, our data had a decreasing number of dually
339 eligible individuals over time. We also did not calculate how oxygen costs compare to total DME
340 expenditures or total Medicare and Medicaid spending. Future studies should examine the cost
341 of oxygen in other populations including privately insured individuals and in national claims
342 databases.

343

344 While our study identified payments made for oxygen claims, we were unable to determine
345 whether oxygen prescriptions were appropriate or whether beneficiaries utilized these oxygen
346 services. Lastly, our small sample of beneficiaries with high flow claims, especially among
347 subjects with ILD, limits our ability to estimate oxygen costs and utilization for these subjects,
348 though it does appear that, for some oxygen equipment, payments are not being increased as
349 per CMS policy. Future studies and investigations are needed to further explore this finding.

350

351 **CONCLUSION**

352 The vast majority of supplemental oxygen claims for Pennsylvania residents dually eligible for
353 Medicaid and Medicare fee-for-service benefits with diagnoses of ILD or COPD were for
354 stationary oxygen concentrators. Subjects with ILD had a greater proportion of paid oxygen
355 claims but represent only a small portion of all oxygen claims. Among users of oxygen
356 concentrators, the addition of liquid oxygen further increases costs compared to gas equipment,
357 however the utilization of liquid oxygen is low in both diseases. Our findings support the
358 concerns raised by other studies that the CMS competitive bidding program may have resulted
359 in decreased access for liquid oxygen services.

360

361 **ACKNOWLEDGEMENTS**

362 Jie Lin, PhD


363

364 **Table 1. Demographic and clinical characteristics of unique individuals at time of first year in**
 365 **the dataset (2016-2020)**

	ILD (n=2,297)	COPD (n=72,412)
Age, mean (SD)	67.6 (14.0)	64.5 (12.4)
Male, N (%)	901 (39.2)	29,574 (40.8)
Race/Ethnicity, N (%)		
<i>Non-Hispanic White</i>	1,392 (60.6)	51,578 (71.2)
<i>Non-Hispanic Black</i>	420 (18.3)	13,226 (18.3)
<i>Hispanic</i>	218 (9.5)	3,673 (5.1)
<i>Other</i>	267 (11.6)	3,935 (5.4)
Home and community-based services	734 (32.0)	18,269 (25.2)
Months with an oxygen claim, median (IQR)	11 (5-12)	12 (6-12)
Non-metro resident, N (%)	330 (14.4)	13,999 (19.3)
Competitive bidding area resident, N (%)	1,489 (64.8)	42,546 (58.8)
Confounders of oxygen use, N (%)		
<i>Current or prior tobacco use</i>	600 (26.1)	30,235 (41.8)
<i>Heart failure</i>	987 (43.0)	21,252 (29.4)
<i>Pulmonary hypertension</i>	457 (19.9)	5,526 (7.6)
Count of other comorbidities, N (%)		
<i>0 to 1</i>	164 (7.1)	8,243 (11.4)
<i>2 to 3</i>	383 (16.7)	17,342 (24.0)
<i>4 to 5</i>	576 (25.1)	19,141 (26.4)
<i>6 to 7</i>	580 (25.3)	15,190 (21.0)
<i>8 to 9</i>	390 (17.0)	8,886 (12.3)
<i>10 or more</i>	204 (8.9)	3,610 (5.0)
Any Oxygen Claim, N (%)	792 (34.5)	13,300 (18.4)
High Flow (>4 L/min) Oxygen Claim, N (%)	37 (1.7)	329 (0.5)


366

367 **Figure 1. Median (IQR) monthly payment for oxygen claims by year**



368
369

370 **Figure 2. Proportion of person-years claims by equipment type**



371
 372 **Note: Categories with <10 observations are redacted**
 373

374 **Table 2. Median (IQR) monthly payment for person-year claims by oxygen equipment type**
 375 **and flow rate**

Equipment Type	ILD				COPD			
	All claims	>4 L/min claims	≤4 L/min claims	p-value*	All claims	>4 L/min claims	≤4 L/min claims	p-value*
Stationary concentrator	\$54.67 (\$29.62-\$74.27)	\$55.03 (\$30.20-\$72.03)	\$54.67 (\$29.55-\$74.53)	0.597	\$56.83 (\$29.55-\$80.00)	\$61.61 (\$35.89-\$86.16)	\$56.74 (\$29.19-\$79.78)	<0.001
Portable concentrator	\$21.20 (\$11.72-\$28.96)	\$22.21 (\$12.88-\$25.32)	\$21.08 (\$11.35-\$29.19)	0.806	\$22.77 (\$11.41-\$29.01)	\$19.37 (\$9.54-\$29.99)	\$22.79 (\$11.42-\$29.01)	0.28
Portable gas	\$12.92 (\$6.64-\$21.92)	\$12.56 (\$6.60-\$21.20)	\$12.96 (\$6.65-\$22.01)	0.113	\$13.78 (\$7.53-\$22.38)	\$14.02 (\$8.58-\$23.57)	\$13.78 (\$7.51-\$22.36)	0.452
Portable liquid	\$16.62 (\$7.77-\$31.27)	--	\$20.18 (\$9.90-\$31.69)	--	\$18.83 (\$11.59-\$32.96)	\$19.28 (\$10.13-\$29.51)	\$18.82 (\$11.59-\$32.99)	0.143
Stationary gas	--	--	--	--	--	--	--	--
Stationary liquid	\$43.05 (\$29.52-\$59.99)	--	\$37.33 (\$24.63-\$59.75)	--	\$45.22 (\$30.72-\$69.02)	--	\$45.22 (\$31.16-\$68.73)	--

376 *p-value compares median payment between >4 L/min and ≤4 L/min claims

377 Note: cells with <10 observations are redacted

378

379 **Table 3. Results of GEE model**

380

381 **Table 3a. Results of a GEE model for repeated measures assessing factors influencing oxygen**
 382 **payments among beneficiaries who had claims paid for stationary oxygen concentrators**

Variable	Coefficient	95% CI	p-value
Age	-45.52	-54.51, -36.53	<0.001
Male	7.14	-10.71, 25.00	0.433
Race/ethnicity ¹			
<i>Non-Hispanic black</i>	26.18	0.51, 51.85	0.046
<i>Hispanic</i>	-13.93	-61.53, 33.68	0.566
<i>Other</i>	49.91	7.20, 92.62	0.022
Non-metro	153.47	129.99, 176.96	<0.001
Competitive bidding area	-65.67	-86.61, -44.74	<0.001
Home and community-based services ²	-93.51	-110.78, -76.24	<0.001
Comorbidity count ³			
2-3	-100.96	-138.45, -63.46	<0.001
4-5	-151.61	-188.22, -115.00	<0.001
6-7	-214.11	-251.07, -177.15	<0.001
8-9	-287.32	-325.82, -248.82	<0.001
10 or more	-327.00	-369.52, -284.48	<0.001
Current or prior tobacco use	-48.69	-66.76, -30.62	<0.001
Heart failure	44.35	25.82, 62.88	<0.001
Pulmonary hypertension	8.79	-13.24, 30.82	0.434
Gas oxygen (portable or stationary)	176.28	159.03, 193.53	<0.001
Liquid oxygen (portable or stationary)	200.48	70.23, 330.72	0.003
Portable oxygen concentrator	317.92	291.85, 343.99	<0.001
High flow (>4 L/min)	28.76	-18.15, 75.67	0.230
ILD diagnosis	19.27	-19.35, 57.89	0.328
_cons	984.08	945.93, 1022.24	<0.001

383 ¹Reference group = non-Hispanic white

384 ²Reference group = 0-1 comorbidity

385 ³Reference group = No home or community-based services

386 **Table 3b. Estimated annual costs of oxygen equipment based on GEE model**

Oxygen Equipment	ILD Annual Cost (95% CI)	COPD Annual Cost (95% CI)
Stationary concentrator only	\$964.36 (\$926.59, \$1022.13)	\$945.09 (\$936.76, \$953.41)
Stationary concentrator + Gas (Portable/Stationary)	\$1027.27 (\$989.06, \$1065.48)	\$1008.00 (\$997.26, \$1018.74)
Stationary concentrator + Liquid (Portable/Stationary)	\$1163.92 (\$1029.19, \$1298.64)	\$1144.65 (\$1014.60, \$1274.69)
Stationary concentrator + Portable Concentrator	\$1241.31 (\$1198.25, \$1284.37)	\$1222.04 (\$1197.29, \$1246.79)

387

388

389 **REFERENCES**

- 390 1. Jacobs SS, Krishnan JA, Lederer DJ, Ghazipura M, Hossain T, Tan AM, et al. Home oxygen
391 therapy for adults with chronic lung disease. An official American Thoracic Society
392 clinical practice guideline. *Am J Respir Crit Care Med* 2020;202(10):e121-e141.
- 393 2. Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease:
394 a clinical trial. Nocturnal Oxygen Therapy Trial Group. *Ann Intern Med* 1980;93(3):391-
395 398.
- 396 3. Long term domiciliary oxygen therapy in chronic hypoxic cor pulmonale complicating
397 chronic bronchitis and emphysema. Report of the Medical Research Council Working
398 Party. *Lancet* 1981;1(8222):681-686.
- 399 4. Khor YH, Renzoni EA, Visca D, McDonald CF, Goh NSL. Oxygen therapy in COPD and
400 interstitial lung disease: navigating the knowns and unknowns. *ERJ Open Res* 2019;5(3).
- 401 5. Wang BR, Edwards R, Freiheit EA, Ma Y, Burg C, de Andrade J, et al. The Pulmonary
402 Fibrosis Foundation Patient Registry. Rationale, Design, and Methods. *Ann Am Thorac*
403 *Soc* 2020;17(12):1620-1628.
- 404 6. Ke X, Marvel J, Yu TC, Wertz D, Geremakis C, Wang L, et al. Impact of lung function on
405 exacerbations, health care utilization, and costs among patients with COPD. *Int J Chron*
406 *Obstruct Pulmon Dis* 2016;11:1689-1703.
- 407 7. Wallace A.E. KS, Bayer V., Shaikh A., Shinde M.U., Willey VJ, Napier MB, Singer JR. Health
408 care resource utilization and exacerbation rates in patients with COPD stratified by
409 disease severity in a commercially insured population. *Journal of Managed Care and*
410 *Specialty Pharmacy* 2019;25(2):205-217.

- 411 8. Stephenson JJ, Wertz D, Gu T, Patel J, Dalal AA. Clinical and economic burden of dyspnea
412 and other COPD symptoms in a managed care setting. *Int J Chron Obstruct Pulmon Dis*
413 2017;12:1947-1959.
- 414 9. Wu N, Yu YF, Chuang CC, Wang R, Benjamin NN, Coultas DB. Healthcare resource
415 utilization among patients diagnosed with idiopathic pulmonary fibrosis in the United
416 States. *J Med Econ* 2015;18(4):249-257.
- 417 10. Collard HR, Ward AJ, Lanes S, Courtney Hayflinger D, Rosenberg DM, Hunsche E. Burden
418 of illness in idiopathic pulmonary fibrosis. *J Med Econ* 2012;15(5):829-835.
- 419 11. Collard HR, Chen SY, Yeh WS, Li Q, Lee YC, Wang A, et al. Health care utilization and costs
420 of idiopathic pulmonary fibrosis in U.S. Medicare beneficiaries aged 65 years and older.
421 *Ann Am Thorac Soc* 2015;12(7):981-987.
- 422 12. Iheanacho I, Zhang S, King D, Rizzo M, Ismaila AS. Economic Burden of Chronic
423 Obstructive Pulmonary Disease (COPD): A Systematic Literature Review. *Int J Chron*
424 *Obstruct Pulmon Dis* 2020;15:439-460.
- 425 13. Dieleman JL, Cao J, Chapin A, Chen C, Li Z, Liu A, et al. US Health Care Spending by Payer
426 and Health Condition, 1996-2016. *JAMA* 2020;323(9):863-884.
- 427 14. Duan KI, Birger M, Au DH, Spece LJ, Feemster LC, Dieleman JL. Health Care Spending on
428 Respiratory Diseases in the United States, 1996-2016. *Am J Respir Crit Care Med*
429 2023;207(2):183-192.
- 430 15. Hardavella G, Karampinis I, Frille A, Sreter K, Rousalova I. Oxygen devices and delivery
431 systems. *Breathe (Sheff)* 2019;15(3):e108-e116.

- 432 16. Centers for Medicaid and Medicare Services (cms.gov). Article - Oxygen and oxygen
433 equipment - policy article (A5214) [Internet]. Baltimore (MD): Centers for Medicare and
434 Medicaid Services; 2023 [updated April 1, 2023; accessed November 18, 2024]. Available
435 from: [https://www.cms.gov/medicare-coverage-](https://www.cms.gov/medicare-coverage-database/view/article.aspx?articleid=52514&ver=61&LCDId=33797&Date=&DocID=L33797&bc=hAAAAAaGAEAAAAAAA&=)
436 [database/view/article.aspx?articleid=52514&ver=61&LCDId=33797&Date=&DocID=L337](https://www.cms.gov/medicare-coverage-database/view/article.aspx?articleid=52514&ver=61&LCDId=33797&Date=&DocID=L33797&bc=hAAAAAaGAEAAAAAAA&=)
437 [97&bc=hAAAAAaGAEAAAAAAA&=](https://www.cms.gov/medicare-coverage-database/view/article.aspx?articleid=52514&ver=61&LCDId=33797&Date=&DocID=L33797&bc=hAAAAAaGAEAAAAAAA&=).
- 438 17. Centers for Medicaid and Medicare Services (cms.gov). Medicare Claims Processing
439 Manual chapter 20 - durable medical equipment, prosthetics, orthotics, and supplies
440 (DMEPOS) [Internet]. Rev 12557. Baltimore (MD): Centers for Medicare and Medicaid
441 Services; 2022 [updated March 28, 2024; accessed November 18, 2024]. Available from:
442 [https://www.cms.gov/Regultions-and-](https://www.cms.gov/Regultions-and-Guidance/Guidance/Manuals/Downloads/clm104c20.pdf)
443 [Guidance/Guidance/Manuals/Downloads/clm104c20.pdf](https://www.cms.gov/Regultions-and-Guidance/Guidance/Manuals/Downloads/clm104c20.pdf).
- 444 18. Centers for Medicaid and Medicare Services (cms.gov). DMEPOS Competitive Bidding -
445 Home [Internet]. Baltimore (MD): Centers for Medicare and Medicaid Services; [updated
446 September 10, 2024; accessed November 18, 2024]. Available from:
447 [https://www.cms.gov/Medicare/Medicare-Fee-for-Service-](https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/DMEPOSCompetitiveBid)
448 [Payment/DMEPOSCompetitiveBid](https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/DMEPOSCompetitiveBid).
- 449 19. Medicare Payment Advisory Commission (medpac.gov). MedPAC Payment Basics
450 Durable Medical Equipment Payment Systems [Internet]. Washington (DC): Medicare
451 Payment Advisory Commission (MedPAC); 2022 [updated October 2022; accessed
452 December 31, 2022]. Available from: [https://www.medpac.gov/wp-](https://www.medpac.gov/wp-content/uploads/2021/11/MedPAC_Payment_Basics_22_DME_FINAL_SEC.pdf)
453 [content/uploads/2021/11/MedPAC_Payment_Basics_22_DME_FINAL_SEC.pdf](https://www.medpac.gov/wp-content/uploads/2021/11/MedPAC_Payment_Basics_22_DME_FINAL_SEC.pdf).

- 454 20. Medicare Payment Advisory Commission (medpac.gov). June 2018 Report to the
455 Congress: Medicare and the Health Care Delivery System [internet]. Washington, DC:
456 [accessed Jan 2, 2023]. Available from: [https://www.medicare.gov/document/http-www-
457 medpac-gov-docs-default-source-reports-
458 jun18-medpacreporttocongress_rev_nov2019_note_sec-pdf/](https://www.medicare.gov/document/http-www-medpac-gov-docs-default-source-reports-jun18-medpacreporttocongress_rev_nov2019_note_sec-pdf/).
- 459 21. Newman D, Barrette E, McGraves-Lloyd K. Medicare Competitive Bidding Program
460 Realized Price Savings For Durable Medical Equipment Purchases. Health Aff (Millwood)
461 2017;36(8):1367-1375.
- 462 22. Duan KI, Obara E, Wong ES, Liao JM, Sabbatini AK, Donovan LM, et al. Supplemental
463 Oxygen Use, Outcomes, and Spending in Patients With COPD in the Medicare
464 Competitive Bidding Program. JAMA Intern Med 2024.
- 465 23. Jacobs SS, Lindell KO, Collins EG, Garvey CM, Hernandez C, McLaughlin S, et al. Patient
466 perceptions of the adequacy of supplemental oxygen therapy. Results of the American
467 Thoracic Society Nursing Assembly Oxygen Working Group Survey. Ann Am Thorac Soc
468 2018;15(1):24-32.
- 469 24. Lindell KO, Collins EG, Catanzarite L, Garvey CM, Hernandez C, McLaughlin S, et al.
470 Equipment, access and worry about running short of oxygen: Key concerns in the ATS
471 patient supplemental oxygen survey. Heart Lung 2019;48(3):245-249.
- 472 25. Dobson A HS, Kilby D, Hu J, DaVanzo JE. Access to home medical equipment: survey of
473 beneficiary, case manager, and supplier experiences: understanding the impact of
474 competitive bidding. August 30, 2023 October 2017.

- 475 26. SOAR Act of 2024, S 3821, 118th Cong (2023-2024). [accessed November 15, 2024].
476 Available from: <https://www.congress.gov/bill/118th-congress/senate-bill/3821>.
- 477 27. Centers for Medicaid and Medicare Services. 2021 DMEPOS Competitive Bidding Areas.
478 [accessed April 20, 2023]. Available from:
479 <https://www.dmecompetitivebid.com/cbic/cbicr2021.nsf/DocsCat/H5O2KFK4HQ>.
- 480 28. Chronic Conditions Data Warehouse. [accessed September 5, 2022]. Available from:
481 <https://www2.ccwdata.org/web/guest/condition-categories-chronic>.
- 482 29. Centers for Medicaid and Medicare Services (cms.gov). CMS Fast Facts. 2023 [updated
483 March 2024; accessed November 18, 2024]. Available from: [https://data.cms.gov/fact-](https://data.cms.gov/fact-sheet/cms-fast-facts)
484 [sheet/cms-fast-facts](https://data.cms.gov/fact-sheet/cms-fast-facts).
- 485 30. Duan KI, Wong ES, Liao JM, Sabbatini AK, Au DH. Long-term trends in home respiratory
486 medical equipment among U.S. Medicare patients, 2013-2019. Am J Respir Crit Care
487 Med 2022;206(4):509-511.
- 488 31. Ding H. DM, Starc A. Getting the price right? The impact of competitive bidding in the
489 Medicare program. July 30, 2022 2021.
- 490 32. Department of Health and Human Services OoIG. Round 2 Competitive Bidding for
491 Oxygen: Continued Access for Vast Majority of Beneficiaries. May 2018 2018.
- 492 33. Cavanaugh S. Providing quality, affordable durable medical equipment for beneficiaries.
493 Centers for Medicare and Medicaid Services; 2016 [updated July 1, 2016; accessed
494 Available from: [https://wayback.archive-](https://wayback.archive-it.org/2744/20161207130006/https://blog.cms.gov/2016/05/17/providing-quality-affordable-durable-medical-equipment-for-beneficiaries/)
495 [it.org/2744/20161207130006/https://blog.cms.gov/2016/05/17/providing-quality-](https://wayback.archive-it.org/2744/20161207130006/https://blog.cms.gov/2016/05/17/providing-quality-affordable-durable-medical-equipment-for-beneficiaries/)
496 [affordable-durable-medical-equipment-for-beneficiaries/](https://wayback.archive-it.org/2744/20161207130006/https://blog.cms.gov/2016/05/17/providing-quality-affordable-durable-medical-equipment-for-beneficiaries/).

- 497 34. American Association for Respiratory Care/American Lung Association/American
498 Thoracic Society (lung.org). Partners Oxygen Policy Brief: Request: Address Needed
499 Reforms in CMS Reimbursement for Supplemental Oxygen [Internet]. [updated August 8,
500 2021; accessed May 26, 2023]. Available from:
501 [https://www.lung.org/getmedia/209550fe-d52b-4a7a-8385-5cbf822f59b4/partners-](https://www.lung.org/getmedia/209550fe-d52b-4a7a-8385-5cbf822f59b4/partners-oxygen-policy-brief-28aug21.pdf)
502 [oxygen-policy-brief-28aug21.pdf](https://www.lung.org/getmedia/209550fe-d52b-4a7a-8385-5cbf822f59b4/partners-oxygen-policy-brief-28aug21.pdf).
- 503 35. Jacobs SS, Lederer DJ, Garvey CM, Hernandez C, Lindell KO, McLaughlin S, et al.
504 Optimizing home oxygen therapy. An official American Thoracic Society Workshop
505 Report. *Ann Am Thorac Soc* 2018;15(12):1369-1381.
- 506 36. LaVeist TA, Perez-Stable EJ, Richard P, Anderson A, Isaac LA, Santiago R, et al. The
507 Economic Burden of Racial, Ethnic, and Educational Health Inequities in the US. *JAMA*
508 2023;329(19):1682-1692.
- 509 37. Nathan SD, Barbera JA, Gaine SP, Harari S, Martinez FJ, Olschewski H, et al. Pulmonary
510 hypertension in chronic lung disease and hypoxia. *Eur Respir J* 2019;53(1).
- 511 38. Nathan SD, Barnett SD, King CS, Provencher S, Barbera JA, Pastre J, et al. Impact of the
512 new definition for pulmonary hypertension in patients with lung disease: an analysis of
513 the United Network for Organ Sharing database. *Pulm Circ*
514 2021;11(2):2045894021999960.
- 515 39. Goobie GC, Carlsten C, Johannson KA, Khalil N, Marcoux V, Assayag D, et al. Association
516 of Particulate Matter Exposure With Lung Function and Mortality Among Patients With
517 Fibrotic Interstitial Lung Disease. *JAMA Intern Med* 2022;182(12):1248-1259.
518

